Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05116878 · ClinicalTrials.gov registry record · NA
Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma
A NA study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT05116878: Clinical Trial NA study, sponsored by Mayo Clinic.
NCT05116878 is a NA study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05116878, a NA study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this research is to develop a therapeutic agent to help improve facial nerve outcomes and ultimately improve long-term quality-of-life following surgical resection of vestibular schwannomas. It is possible the therapeutic agent may impact tumor control rates as well, and this will also be studied. Using rigorous scientific methods, we will assess whether these factors are impacted by the treatment agent (Omega-3) versus placebo control (cellulose).
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Omega-3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2023-08-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05116878
The ClinicalTrials.gov registry entry for NCT05116878 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05116878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05116878 about?
NCT05116878 is a clinical study titled "Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma". The purpose of this research is to develop a therapeutic agent to help improve facial nerve outcomes and ultimately improve long-term quality-of-life following surgical resection of vestibular schwannomas. It is possible the therapeutic agent may impact tumor control rates as well, and this will als...
What is the current status of trial NCT05116878?
This trial is currently terminated. It is a NA study. The enrollment target is 15 participants. The study started on 2021-11-01. Estimated completion is 2023-08-02.
What interventions are being tested in trial NCT05116878?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Omega-3 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05116878?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.